Tirzepatide

Product Description

Tirzepatide is a novel synthetic peptide that functions as a dual agonist of both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. It is studied for its remarkable effects on glucose regulation, insulin sensitivity, and body weight reduction in metabolic and endocrinological research models.

Benefits (Based on Preclinical Research)

• Enhances insulin secretion and glucose-dependent response

• Promotes significant body fat reduction while preserving lean mass

• Improves insulin sensitivity and beta-cell function

• Suppresses appetite and delays gastric emptying

• Studied in models of obesity, type 2 diabetes, and metabolic syndrome

Who Uses This
Tirzepatide is used by researchers in endocrinology, obesity, and metabolic disease studying dual-incretin therapies for weight management and glucose regulation.

Why Choose Tirzepatide

• Dual GLP-1 and GIP receptor agonist for synergistic effect

• Supplied sterile and lyophilized for research-grade use

• Batch-tested and supplied with Certificate of Analysis

• Demonstrates superior efficacy compared to GLP-1 monotherapies in trials

Documentation and Quality
Each vial is manufactured under sterile conditions and tested via HPLC and MS. Shipped cold-chain with tamper-evident packaging and full research documentation.

Disclaimer
Tirzepatide is intended for research use only. Not approved for therapeutic, human, or veterinary use. Use is restricted to qualified research professionals and certified laboratories.